Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656359 | 0.85 | KCNH2 (0.44) | HTR1AKCNH2 | |
| SCHEMBL14573152 | 0.85 | KCNH2 (0.44) | KCNH2ALDH1A1LMNAHPGD | |
| SCHEMBL14573158 | 0.85 | SLC2A1 (0.43) | KCNH2PDE4B | |
| SCHEMBL5659991 | 0.85 | SLC2A1 (0.43) | KCNH2PDE4B | |
| SCHEMBL5765149 | 0.85 | SLC2A1 (0.43) | KCNH2PDE4B | |
| Hydrochloric Acid SCHEMBL5655525 | 0.84 | SLC2A1 (0.42) | KCNH2PDE4B | |
| SCHEMBL5765739 | 0.84 | ALDH1A1 (0.40) | HTR1AHTR1DHTR1BKCNH2ALDH1A1 | |
| SCHEMBL6667019 | 0.81 | KCNH2 (0.45) | KCNH2ALDH1A1LMNAHPGD | |
| SCHEMBL5751074 | 0.80 | NPC1 (0.41) | KCNH2ALDH1A1LMNAHPGD | |
| SCHEMBL14610730 | 0.76 | KCNH2 (0.51) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186730-B2 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-03-06 | — | — | US | disclosed |
| EP-1392686-B1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2006-10-18 | — | — | EP | disclosed |
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1392686-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002096907-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | NRDC, NUCB2, ASNS | HTR1A 3274/4885HTR1D 1537/4885HTR1B 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.